Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition

AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test

June 13, 2016 7:30 AM EDT

CareDx at the Forefront of Personalized Medicine in Transplantation

CareDx to hold Conference Call on June 13, 2016 at 4pm ET

BRISBANE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, reported the first results of increased levels of donor-derived cell-free DNA (dd-cfDNA) with acute kidney rejection to the DART study clinical investigators attending the American Transplant Congress. The study demonstrated increased levels of dd-cfDNA in acute rejection using the... More